TICKERNERD
Menu
IBIOIBIOHealthcare · Biotechnology

IBIO Stock Forecast: iBio, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$1.44
−2.04% on the day

The 8 Wall Street analysts covering iBio, Inc. hold a median 12-month price target of $5 — +247.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 26 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$71.0M
Ticker Nerd rank
26 / 100
Median analyst target
$5.00
Analysts covering
8
Total return, dividends reinvested
1W
+0.7%
1M
+2.1%
YTD
−25.4%
1Y
+84.6%
From 52W high
−53.1%
From 52W low
+84.6%
$0.78
$3.07
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IBIO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores iBio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
26 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
79
Accruals
67
Momentum
52
Growth
43
Revisions
42
Issuance
39
Volatility
21
Quality
16
Value
8

Size (79): Smaller than most of the companies we track.

Value (8): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IBIO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IBIO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00Oct 25Jan 26Apr 26Jul 26IBIOHigh $7.00Median $5.00Low $4.20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says8 analysts
8 Buy0 Hold0 Sell
Low $4.20Median $5.00High $7.00

The green dot is the last close — the median target sits +247.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
2 July 2026Chardan CapitalMaintainsBuy$5.00
8 June 2026Raymond JamesInitiatesOutperform—
9 Apr 2026Chardan CapitalMaintainsBuy—
18 Mar 2026Chardan CapitalMaintainsBuy—
3 Mar 2026Jones TradingInitiatesBuy—
12 Feb 2026Chardan CapitalMaintainsBuy—
21 Oct 2025OppenheimerInitiatesOutperform—
17 Oct 2025Leerink PartnersInitiatesOutperform—
25 June 2025Chardan CapitalMaintainsBuy—
6 May 2025Chardan CapitalMaintainsBuy—
5 May 2025Chardan CapitalMaintainsBuy—
17 Dec 2024LUCID CAPITAL MARKETSInitiatesBuy—
22 July 2024Brookline CapitalInitiatesBuy—
3 June 2024Chardan CapitalMaintainsBuy—
28 May 2024Chardan CapitalInitiatesBuy—
16 Feb 2023JMP SecuritiesDowngradeMarket Perform—
7 Oct 2022Cantor FitzgeraldDowngradeNeutral$2.50 → $0.17
29 Nov 2021JMP SecuritiesInitiatesOutperform$1.50
22 Jan 2021Cantor FitzgeraldInitiatesOverweight—
21 Jan 2021Cantor FitzgeraldInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IBIO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

IBIO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

iBio, Inc. (IBIO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.6×

Cheaper than 71% of US stocks

Price / sales
236.8×

Cheaper than 3% of US stocks

Price / book
0.6×

Cheaper than 83% of US stocks

EV / EBITDA
0.1×

Cheaper than 61% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
−9653.0%

Higher than 2% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−62.1%

Higher than 18% of US stocks

Return on assets
−34.5%

Higher than 12% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

IBIO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IBIOiBio, Inc.$71.0M
26
OSTXOS Therapies, Inc.$70.8M
29
LONALeonaBio, Inc.$71.5M
44
PLRXPliant Therapeutics, Inc.$71.5M
66
PMVPPMV Pharmaceuticals, Inc.$70.5M
68
RNTXRein Therapeutics, Inc.$70.0M
37
XBITXBiotech, Inc.$69.5M
32

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own iBio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IBIO news & analysis

iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer

GlobeNewsWire · 4 Aug 2026positive

iBio, Inc. announced the appointment of endocrinologist Molly Carr, M.D., as Chief Medical Officer. Dr. Carr, who has over 30 years of clinical, academic and biopharmaceutical experience, will lead the company's global clinical strategy, medical affairs, and regulatory initiatives as it advances its cardiometabolic pipeline toward late-stage development.

Why it matters — For IBIO watchers, the appointment adds an experienced endocrinology and metabolic disease executive to lead clinical strategy as the company advances its clinical-stage cardiometabolic pipeline toward later-stage development.

FAQ

Frequently asked questions about IBIO stock

What is the IBIO stock price forecast for 2026-2027?

The 8 Wall Street analysts covering iBio, Inc. have a median 12-month price target of $5, with estimates ranging from $4.2 to $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IBIO stock a buy right now?

Of the 8 analysts covering iBio, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks iBio, Inc. 26 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IBIO?

As at 22 Aug 2026, iBio, Inc. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (79 of 100).

Will IBIO stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +247.2% from the last close, and Ticker Nerd's factor model ranks iBio, Inc. 26 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IBIO stock forecast for 2030?

No analyst covering iBio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IBIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4.2 to $7 over the next 12 months.

How has IBIO stock performed over the past year?

iBio, Inc. returned +84.6% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does iBio, Inc. do?

iBio Inc. is a preclinical-stage biotechnology company developing next-generation biopharmaceuticals by leveraging artificial intelligence and advanced computational biology.

What is the latest news on IBIO?

The most recent item we track (GlobeNewsWire, 4 Aug 2026): "iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer". iBio, Inc. announced the appointment of endocrinologist Molly Carr, M.D., as Chief Medical Officer. Dr. Carr, who has over 30 years of clinical, academic and biopharmaceutical experience, will lead the company's global clinical strategy, medical affairs, and regulatory initiatives as it advances its cardiometabolic pipeline toward late-stage development.

Company

About iBio, Inc.

iBio Inc. is a preclinical-stage biotechnology company developing next-generation biopharmaceuticals by leveraging artificial intelligence and advanced computational biology. The company focuses on creating novel antibody-based therapies for cardiometabolic diseases, obesity, cancer, and other difficult-to-treat conditions. iBio's proprietary technology platforms include EngageTx for enhanced T-cell engager antibodies, ShieldTx for conditionally activated antibodies, and StableHu for AI-assisted antibody optimization. The company integrates AI with experimental biology to design antibodies targeting previously undruggable proteins, emphasizing precision, speed, and real-world patient impact. iBio's pipeline includes IBIO-101 for solid tumors, CCR8 for cancer immunotherapy, and EGFRvIII for specific cancer types. Through a collaboration with AstralBio, iBio is also advancing novel antibody therapies for obesity and cardiometabolic disease. Headquartered in San Diego, California, and incorporated in 2008, iBio aims to transform drug discovery and accelerate development timelines in precision medicine.

CEO Dr. Martin B. Brenner D.V.M., Ph.D. · 20 employees · United States · https://ibioinc.com